key: cord-0959961-dw1zdzye
authors: Chiricozzi, Andrea; Garcovich, Simone; Malvaso, Dalma; Giovanardi, Giulia; Peris, Ketty
title: COVID‐19 occurrence in one secukinumab‐treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus
date: 2020-09-23
journal: Int J Dermatol
DOI: 10.1111/ijd.15209
sha: 828715a8d33640945937771cbe0eb7570d03485b
doc_id: 959961
cord_uid: dw1zdzye

nan

geal swab results were negative and secukinumab therapy was reintroduced after 8 weeks from the last administration.

A 28-year-old woman presented with SLE since the age of 13, with renal involvement (class III nephritis), myocarditis, and antiphospholipid antibody syndrome that was previously treated with hydroxychloroquine and salicylic acid. Medical history also included autoimmune thyroiditis, fibromyalgia, and osteoporosis.

First manifestations of HS were reported at the age of 20 years.

Frequent flares (>2 episodes/months) occurred, and minimal clinical and ultrasonographic improvements were obtained with previous HS-specific treatments. At our observation (Fig. 1a) , the patient reported a worsening of disease associated with a relevant disease burden (Hurley II; IHS4: 12; pain-Numeric Rat- 

Anti-tumor necrosis factor-a induced systemic lupus erythematosus

Open-label, investigator-initiated, single-site exploratory trial evaluating secukinumab, an anti-interleukin-17A monoclonal antibody, for patients with moderate-to-severe hidradenitis suppurativa

Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial

A case of refractory lupus nephritis complicated by psoriasis vulgaris that was controlled with secukinumab

Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study